HIMS — Hims & Hers Health, Inc.

Is HIMS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Neutral As of July 5, 2026

Hims & Hers Health, Inc. (HIMS) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $36.80. The rating moved from Overbought to Neutral on July 1, 2026 and has changed 21 times in the last 90 days.

Public ratingNeutral (as of July 5, 2026)
Last close$36.80
Rating changesRating changed 21 times in the last 90 days
Last changeMoved from Overbought to Neutral on July 1, 2026
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Latest MarketMoodz coverage

Hims & Hers tumbles 16% on Q1 loss, weak full-year guidance2026-05-12
Hims & Hers, GitLab Drive After-Hours Moves Amid Guidance, Restructuring2026-05-11
Amazon Debuts GLP-1 Weight-Loss Program via One Medical2026-04-21
Allbirds, Hims & Hers, Microsoft, Xanadu, Tesla: Stocks on Investors' Radar2026-04-16
Novo Nordisk launches multi-month Wegovy subscriptions2026-03-31

See today's live rating, score and targets

Members see the live hourly rating for HIMS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.